KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of Deferred ChargesAmortizatization of IntangiblesBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pacira BioSciences (PCRX) Cash from Operations: 2009-2024

Historic Cash from Operations for Pacira BioSciences (PCRX) over the last 16 years, with Dec 2024 value amounting to $189.4 million.

  • Pacira BioSciences' Cash from Operations rose 12.82% to $60.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $141.4 million, marking a year-over-year decrease of 30.61%. This contributed to the annual value of $189.4 million for FY2024, which is 22.46% up from last year.
  • Per Pacira BioSciences' latest filing, its Cash from Operations stood at $189.4 million for FY2024, which was up 22.46% from $154.6 million recorded in FY2023.
  • Pacira BioSciences' 5-year Cash from Operations high stood at $189.4 million for FY2024, and its period low was $77.0 million during FY2020.
  • Its 3-year average for Cash from Operations is $163.1 million, with a median of $154.6 million in 2023.
  • Per our database at Business Quant, Pacira BioSciences' Cash from Operations soared by 63.20% in 2021 and then dropped by 6.45% in 2023.
  • Pacira BioSciences' Cash from Operations (MRY) stood at $77.0 million in 2020, then skyrocketed by 63.20% to $125.7 million in 2021, then rose by 15.56% to $145.3 million in 2022, then grew by 6.45% to $154.6 million in 2023, then rose by 22.46% to $189.4 million in 2024.
  • Its Cash from Operations was $189.4 million in FY2024, compared to $154.6 million in FY2023 and $145.3 million in FY2022.